A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability, and Pharmacokinetics Study of Escalating Single Doses of MLN3126 in Healthy Subjects

Trial Profile

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability, and Pharmacokinetics Study of Escalating Single Doses of MLN3126 in Healthy Subjects

Discontinued
Phase of Trial: Phase I

Latest Information Update: 12 Mar 2016

At a glance

  • Drugs MLN 3126 (Primary)
  • Indications Unspecified
  • Focus Adverse reactions
  • Sponsors Takeda
  • Most Recent Events

    • 12 Mar 2016 Results of this and other trial (see profile 248090) presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
    • 23 May 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top